cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Puma Biotechnology Inc
19 own
54 watching
Current Price
$2.97
$-0.05
(-1.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
163.79M
52-Week High
52-Week High
7.73000
52-Week Low
52-Week Low
2.23000
Average Volume
Average Volume
0.54M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization163.79M
icon52-Week High7.73000
icon52-Week Low2.23000
iconAverage Volume0.54M
iconDividend Yield--
iconP/E Ratio--
What does the Puma Biotechnology Inc do?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Read More
How much money does Puma Biotechnology Inc make?
News & Events about Puma Biotechnology Inc.
Benzinga
1 year ago
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. read more...
Business Wire
2years ago
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer to in meetings beginning Monday, January 9, 2023. The updated presentation includes, among other...
Benzinga
2years ago
On Tuesday, shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) experienced volatile short activity. After the activity, the stock price went up +3.99% to $3.26. The overall sentiment for PBYI has been Bullish. read more...
Business Wire
2years ago
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer (NSCLC) patients at the EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium that is...
Business Wire
2years ago
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress, currently...
Frequently Asked Questions
Frequently Asked Questions
What is Puma Biotechnology Inc share price today?
plus_minus_icon
Can Indians buy Puma Biotechnology Inc shares?
plus_minus_icon
How can I buy Puma Biotechnology Inc shares from India?
plus_minus_icon
Can Fractional shares of Puma Biotechnology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Puma Biotechnology Inc stocks?
plus_minus_icon
What is today’s traded volume of Puma Biotechnology Inc?
plus_minus_icon
What is today’s market capitalisation of Puma Biotechnology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Puma Biotechnology Inc?
plus_minus_icon
What percentage is Puma Biotechnology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Puma Biotechnology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.97
$-0.05
(-1.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$32.42
$0.60 (1.89 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.00
$-0.03 (-0.99 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$0.84
$-0.01 (-0.83 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$110.05
$6.10 (5.87 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$32.42
$0.60 (1.89 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.00
$-0.03 (-0.99 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$0.84
$-0.01 (-0.83 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$110.05
$6.10 (5.87 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00